Key Takeaways
- The European Medicines Agency has started reviewing the marketing authorization applications for eight new drugs – tolebrutinib, lenacapavir, levodopa/carbidopa, estetrol, aflibercept, teriparatide, and two midazolam products.
Tolebrutinib, Sanofi’s investigational treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is among the latest products that the European Medicines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?